State Street
BCAX

State Street’s Bicara Therapeutics BCAX Stock Holding History

State Street’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.8M Buy
2,048,920
+629,532
+44% +$14M ﹤0.01% 1735
2026
Q1 		$28.2M Sell
1,419,388
-230,149
-14% -$3.96M ﹤0.01% 2052
2025
Q4 		$27.8M Buy
1,649,537
+1,059,260
+179% +$18.1M ﹤0.01% 2073
2025
Q3 		$9.32M Buy
590,277
+49,210
+9% +$551K ﹤0.01% 2678
2025
Q2 		$5.03M Buy
541,067
+170,936
+46% +$2.04M ﹤0.01% 2941
2025
Q1 		$4.82M Buy
370,131
+65,400
+21% +$868K ﹤0.01% 2899
2024
Q4 		$5.31M Buy
+304,731
New +$6.34M ﹤0.01% 2944

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's BCAX Position: Q2 2026 in Review

State Street increased its Bicara Therapeutics (BCAX) stake by 44% in Q2 2026, buying an estimated $14M and bringing the position to 2,048,920 shares worth $60.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

State Street first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • State Street held 2,048,920 shares of Bicara Therapeutics worth $60.8M as of Q2 2026.
  • State Street bought 629,532 Bicara Therapeutics shares in Q2 2026, an estimated $14M.
  • Bicara Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1735 holding.
  • State Street first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.